CD22 and acute lymphoblastic leukemia: Commercially available is lnotuzumab ozogamicin (Besponsa), a calicheamicin immunoconjugate developed by Pfizer for the treatment of CD22-positive B-cell precursor acute lymphoblastic leukemia (B-ALL), which subsequently showed high efficiency against acute lymphoblastic leukemia (ALL) [63].